NULIBRY is a first-in-class cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A.
Phase 2 study evaluating an investigational weekly oral combination treatment regimen of islatravir and Gilead Sciences’ lenacapavir to resume with lower dose of islatravir
Azelis’ customers now have access to products including the well-established Polyglykol portfolio, as well as a brand-new range of Motusflex and VitiPure excipients.
Singapore presents great opportunities for the adoption of technology in healthcare and is open for investments
Coordinated by the Medical University of Vienna, a consortium of 13 leading European organizations including university hospitals, research institutions and healthcare companies will conduct the 5-year project co-funded by Horizon Europe.
Evusheld significantly reduced risk of severe COVID-19 or death in TACKLE Phase III treatment trial
Dolomite Bio scientist demonstrating pipetting into the Nadia Go
Quinten Health will announce in the coming months strategic partnerships with big pharma companies and data owners to launch the first disease modeling platforms.
Expanding precision medicine, ARTIS icono is designed to enable a wide procedure mix in a single interventional suite
The campaign will also focus on providing doorstep TB screening services to facilitate diagnosis
Subscribe To Our Newsletter & Stay Updated
